Skip to main
HRMY
HRMY logo

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 33%
Hold 0%
Sell 7%
Strong Sell 7%

Bulls say

Harmony Biosciences Holdings Inc. has demonstrated a positive trajectory with its flagship product, WAKIX, achieving net revenues of $201.3 million in 4Q24, reflecting a 20% year-over-year increase, indicative of strong market demand and effective adoption strategies. The company is projected to significantly increase WAKIX sales, with estimates growing from approximately $160 million in 2020 to over $700 million by 2024, driven by a robust prescriber penetration exceeding 50% among a targeted prescriber base. Additionally, the company's expansion into orphan drug candidates, including those in pipeline phases for conditions such as Prader-Willi Syndrome and Dravet Syndrome, positions Harmony favorably to drive future growth and enhance shareholder value.

Bears say

Harmony Biosciences Holdings Inc. faces significant financial challenges, as evidenced by the removal of potential revenues from its key product WAKIX in the idiopathic hypersomnia (IH) market, leading to a $5 reduction in the estimated value of the pitolisant pipeline. Additionally, there are substantial risks including potential competition from sodium oxybate, a decline in the acquisition of new patients for WAKIX, and the uncertain outcomes of ongoing clinical trials for multiple drug candidates in the pipeline. The cumulative effect of these factors has resulted in a downward revision of the company's price target, which reflects growing concerns about future revenue growth and market position.

HRMY has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 15 analysts, HRMY has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.